Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.34915
+0.0002 (0.04%)
Nov 6, 2026, 4:00 PM EST - Market closed
Oragenics Employees
Oragenics had 3 employees as of December 31, 2025. The number of employees decreased by 2 or 40.00% compared to the previous year. That makes Oragenics the 42,800th largest employer in the world and 6,790th in the United States.
Employees
3
Change (1Y)
-2
Growth (1Y)
-40.00%
Revenue / Employee
n/a
Profits / Employee
-$3,361,136
Market Cap
1.58M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 3 | -2 | -40.00% | 3 | 0 |
| Dec 31, 2024 | 5 | 0 | - | 3 | 2 |
| Dec 31, 2023 | 5 | -1 | -16.67% | 5 | 0 |
| Dec 31, 2022 | 6 | 1 | 20.00% | 6 | 0 |
| Dec 31, 2021 | 5 | -2 | -28.57% | 5 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Enlivex | 34 |
| PMGC Holdings | 34 |
| GeoVax Labs | 19 |
| BioRestorative Therapies | 14 |
| Genprex | 13 |
| Kairos Pharma | 4 |
| XORTX Therapeutics | 3 |
OGEN News
- 7 weeks ago - Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum - GlobeNewsWire
- 2 months ago - Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update - GlobeNewsWire
- 4 months ago - Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling - GlobeNewsWire
- 5 months ago - Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21 - GlobeNewsWire
- 5 months ago - ORAGENICS PROVIDES INVESTOR UPDATE - GlobeNewsWire
- 6 months ago - Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation - GlobeNewsWire
- 6 months ago - Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. - GlobeNewsWire
- 6 months ago - Oragenics announces 8 drug doses administered in Phase IIa trial of ONP-002 - TheFly